One potential explanation for the lack of benefit is that PCa patients with “weak” expression of mTOR pathways showing adverse pathological features and a greater risk of BCR are unlikely to benefit from mTOR inhibitor therapies. The gene discussed is BCR; the disease is posterior cortical atrophy.